Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1554 of 5804
-
New study checks safety of combined heart valve and aorta graft
Disease control Recruiting nowMulticenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New heart valve procedure shows promise for severe aortic stenosis
Disease control OngoingEvaluation of TAVR using the NAVITOR valve in a Global Investigation.
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New Immune-Guiding drug shows promise in advanced prostate cancer trial
Disease control OngoingThe purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New trial tests faster radiation for men with spread prostate cancer
Disease control Recruiting nowWe will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Se…
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug could tame lupus skin flares
Disease control OngoingThe purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biol…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:30 UTC
-
Experimental immune cell therapy shows promise for Tough-to-Treat colon cancer
Disease control CompletedThis is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
Phase: PHASE2 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spinal stimulation trial hopes to restore movement and bladder control
Symptom relief Recruiting nowNeurological disability caused by traumatic lesions of the spinal cord is a significant challenge for medicine and society. These lesions, leading to sublesional central nervous system dysfunction, include sensorimotor, vesico-sphincter and genito-sexual disorders. To date, there…
Phase: NA • Sponsor: Hopital Foch • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Experimental brain tumor cocktail targets recurrent glioma
Disease control Recruiting nowThis is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope against deadly mold infections: generic drug shows promise
Disease control CompletedAmphotericin B Cholesteryl Sulfate Complex (ABCD) is a generic drug of amphotericin B colloidal dispersion. This study aimed to explore the safety and efficacy of ABCD in patients with invasive mold disease.
Phase: PHASE3 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New antibody shows promise for painful skin condition
Disease control CompletedEfficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for c…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New injection shows promise for controlling high blood pressure
Disease control CompletedThe purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo aims to control lung cancer that returns after standard therapy
Disease control Recruiting nowThis phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after ch…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Magnetic pulses to the brain could curb alcohol cravings
Disease control Recruiting nowThe purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techn…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New gel pump for Parkinson's: Real-World results under scrutiny
Disease control OngoingThis observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia). Lecigon® is prescribed by physicians in advanced Parki…
Sponsor: Britannia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Which blood thinner is safer? major trial pits rivaroxaban against apixaban
Disease control Recruiting nowAtrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be f…
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New radiation approach aims to stop pancreatic cancer return after surgery
Disease control OngoingWhile surgery is considered the only potentially curative therapy for pancreatic cancer, 5-year overall survival (OS) is typically \<25%. Following surgical resection of pancreatic cancer, adjuvant conventionally fractionated RT (CRT, delivering 45-54 Gy in 1.8-2.0 Gy per fractio…
Phase: NA • Sponsor: Istituto Clinico Humanitas • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Blood test could spot lingering lung cancer after surgery
Knowledge-focused Recruiting nowctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control OngoingThe purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding coh…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a nightly eye drop tame severe nearsightedness in kids?
Disease control CompletedObjective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropi…
Phase: NA • Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC